Despite a detailed pipeline update in this PR, there is no mention of the RDEA806 program in HIV, which leads me believe that the program is effectively dead. I presume that RDEA shopped the program to various partners and found no interest. (RDEA had previously stated that it would not advance the program into phase-2b without a partner.)
The RDEA806 program in gout remains fully active, and the company has evidently settled on gout and cancer as its new foci.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.